LC-MS Assessment of Human Metabolism Compliance with "MIST" Guidance

E-Separation Solutions

Tuesday afternoon's session titled "LC?MS Assessment of Human Metabolism Compliance with "MIST" Guidance" plans to tackle the topic of the key challenges for drug development as a result of the FDA?s MIST guidance.

Tuesday afternoon's session titled "LC–MS Assessment of Human Metabolism Compliance with "MIST" Guidance" plans to tackle the topic of the key challenges for drug development as a result of the FDA’s MIST guidance.

The first presentation, "A New Paradigm for Metabolite Profiling and Bioanalysis to Identify and Manage Metabolite Safety Concerns," will be given by Scott W. Grimm of AstraZeneca Pharmaceuticals. This presentation will reportedly provide an overview of the new challenges facing biotransformation and bioanalytical scientists in the pharmaceutical industry.

Following AstraZeneca's presentation will be, "A Methodology for Complete Plasma Metabolite Profiling and Identification with High-Resolution LC/MS to Address MIST Issues in Early Clinical Studies," by Haiying Zhang and a team from Bristol-Myers Squibb. The application presented will reportedly demonstrate the practicality of this complete metabolite profiling methodology for assessment of exposures of human metabolites with non-radiolabeled compounds.

The next presentation scheduled is from Natalia Penner of Schering-Plough and is called "Metabolite Profiling Challenges in the First-in-Human Study. Identification of Two Novel Metabolites of a Nociceptin Agonist." This presentation will focus on the structural elucidation of two unique metabolites detected in the process of metabolite characterization in plasma and urine from first-in-human study.

Following up this presentation will be one from Richard Clayton of Covance Laboratories, Ltd. entitled, "A Review of Accurate Mass LC–MS Applications for Compliance with MIST Guidelines." This talk will cover samples from a variety of early development studies that can be used to address questions raised by publication of FDA guidelines.

"A Retention-Time-Shift-Tolerant Background-Subtraction and Noise-Reduction Algorithm (BgS-NoRA) for Extraction of Drug Metabolites in LC–MS Data," will be the second to last presentation of the session given by Peijuan Penny Zhu of Schering-Plough Research Institute. This talk will address issues with the MIST guidelines, a retention-time-shift-tolerant background subtraction, and the noise reduction algorithm that was implemented using R to remove matrix ions from accurate mass liquid chromatography mass spectrometry data.

The final presentation from this session, "Rapid Detection and Characterization of N-acetyl-L-Cysteine Conjugates in Human Urine Using Polarity Switching of Quadrupole-Linear Ion Trap Mass Spectrometry," will be given by Wenying Jian from Bristol-Myers Squibb. The talk will discuss a novel methodology for rapid and sensitive detection and structure characterization of NAC conjugates using polarity switching of Q-Trap.